Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2-metastatic breast cancer treated with CDK4/6 inhibitors

被引：0
|
作者：
Antras, Jesus Fuentes
El Ghamrasni, Samah
Zou, Jinfeng
Dou, Aaron
Elliott, Mitchell J.
Avery, Lisa
Bratman, Scott Victor
Cescon, David W.
Bedard, Philippe L.
机构：
[1] Univ Hlth Network, Div Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Univ Toronto, Univ Hlth Network, Dept Biostat, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1075
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2-metastatic breast cancer
    Zhao, Joseph J.
    Fong, Khi Yung
    Chan, Yiong Huak
    Tey, Jeremy Chee Seong
    Dawood, Shaheenah S.
    Lee, Soo-Chin
    Finn, Richard S.
    Sundar, Raghav
    Lim, Joline S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Treatment patterns for young women with HR+/HER2-metastatic breast cancer in the United States in the era of CDK 4/6 inhibitors
    Burstein, Harold J.
    Mayer, Erica L.
    DeMichele, Angela
    Harnett, James
    Mardekian, Jack
    McRoy, Lynn
    Bartlett, Cynthia Huang
    Koehler, Maria
    Rimawi, Mothaffar Fahed
    CANCER RESEARCH, 2018, 78 (04)
  • [23] Analyzing the changes in the HR+/HER2-metastatic breast cancer (mBC) landscape since the arrival of CDK4/6 inhibitors with machine learning and visual analytics
    Meade, D.
    Alford, S. Hensley
    Mahatma, S.
    Malangone-Monaco, E.
    Boulanger, L.
    Tkacz, J.
    Turner, S. J.
    Chen, S.
    Manson, S.
    Mejia, S.
    Buleje, I.
    Madan, P.
    Kim, G.
    Fowler, R.
    Basar, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [24] Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2-metastatic breast cancer in postmenopausal women in Panama
    Castillo-Fernandez, Omar O.
    Lim, Maria
    Montano, Lilian
    CANCER RESEARCH, 2023, 83 (05)
  • [25] HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2-metastatic breast cancer
    Shah, Payal Deepak
    Torres, Alexandra
    Aaron, Megan
    Narayan, Vivek
    Knollman, Hayley Michelle
    Bradbury, Angela R.
    DeMichele, Angela
    Robson, Mark E.
    Tung, Nadine M.
    Domchek, Susan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Real world incidence and management of adverse events in patients with HR+, HER2-metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting
    Price, Gregory L.
    Sudharshan, Lavanya
    Ryan, Paula
    Rajkumar, Jonathan
    Sheffield, Kristin M.
    Smyth, Emily Nash
    Guimaraes, Claudia Morato
    Rybowski, Sarah
    Carter, Gebra Cuyun
    Gathirua-Mwangi, Wambui Grace
    Huang, Yu-Jing
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (08) : 1319 - 1331
  • [27] The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2-Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered
    Pilehvari, Asal
    You, Wen
    Kimmick, Gretchen
    Camacho, Fabian
    Bonilla, Gloribel
    Anderson, Roger
    CLINICAL DRUG INVESTIGATION, 2025, 45 (02) : 59 - 68
  • [28] Optimizing CDK4/6 inhibitors in advanced HR+/HER2-breast cancer: A personalized approach
    Fontanella, Caterina
    Giorgi, Carlo Alberto
    Russo, Stefania
    Angelini, Silvia
    Nicolardi, Linda
    Giarratano, Tommaso
    Frezzini, Simona
    Pestrin, Marta
    Palleschi, Dario
    Bolzonello, Silvia
    Parolin, Veronica
    Haspinger, Eva R.
    De Rossi, Costanza
    Greco, Filippo
    Gerratana, Lorenzo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 180
  • [29] Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients
    Yifan Wu
    Tao Ouyang
    Jinfeng Li
    Tianfeng Wang
    Zhaoqing Fan
    Tie Fan
    Benyao Lin
    Ye Xu
    Yuntao Xie
    Breast Cancer Research and Treatment, 2020, 179 : 605 - 614
  • [30] Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2-Early Breast Cancer
    Klocker, Eva Valentina
    Egle, Daniel
    Bartsch, Rupert
    Rinnerthaler, Gabriel
    Gnant, Michael
    DRUGS, 2025, 85 (02) : 149 - 169
12345